NCT07012135 Deciphering Preserved Autonomic Function After Multiple Sclerosis
| NCT ID | NCT07012135 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Multiple Sclerosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 13 participants |
| Start Date | 2025-09-17 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 13 participants in total. It began in 2025-09-17 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study looks to characterize gradients of dysfunction in the autonomic nervous system in patients with clinically diagnosed multiple sclerosis. The autonomic nervous system plays key roles in regulation of blood pressure, skin blood flow, and bladder health- all issues that individuals with multiple sclerosis typically suffer. Focusing on blood pressure regulation, the most precise metric with broad clinical applicability, the investigators will perform laboratory-based tests to probe the body's ability to generate autonomic responses. For both individuals with multiple sclerosis and uninjured controls, laboratory-based experiments will utilize multiple parallel recordings to identify how the autonomic nervous system is able to inhibit and activate signals. The investigators anticipate that those with autonomic dysfunction with multiple sclerosis will exhibit abnormalities in these precise metrics. The investigators will look to see if any substantial connections exist between different degrees of preserved autonomic function and secondary autonomic complications from multiple sclerosis. In accomplishing this, the investigators hope to give scientists important insights to how the autonomic nervous system works after multiple sclerosis and give physicians better tools to manage these secondary autonomic complications.
Eligibility Criteria
Inclusion Criteria: * 18-50 years old * clinically confirmed diagnosis of multiple sclerosis -OR- uninjured control Exclusion Criteria: * symptoms of cardiovascular (including, but not limited to: hypertension, stroke, chest pain, etc.), respiratory, peripheral neurological or autonomic disease (particularly diabetes mellitus requiring treatment) * women who are pregnant or lactating * having a body mass index (BMI) ≥ 35 kg/m2 * taking or being administered a medication known to potentially have adverse interactions with phenylephrine * in the judgement of the principal investigator or clinical collaborator, any illness or condition that will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
Contact & Investigator
Ryan J. Solinsky, MD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT07012135 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07012135 currently recruiting?
Yes, NCT07012135 is actively recruiting participants. Contact the research team at lund.erin@mayo.edu for enrollment information.
Where is the NCT07012135 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT07012135 clinical trial?
NCT07012135 is sponsored by Mayo Clinic. The principal investigator is Ryan J. Solinsky, MD at Mayo Clinic. The trial plans to enroll 13 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.